title: The p14ARF alternate reading frame protein enhances DNA binding of topoisomerase I by interacting with the serine 506-phosphorylated core domain.
abstract: In addition to its well-characterized function as a tumor suppressor, p14ARF (ARF) is a positive regulator of topoisomerase I (topo I), a central enzyme in DNA metabolism and a target for cancer therapy. We previously showed that topo I hyperphosphorylation, a cancer-associated event mediated by elevated levels of the protein kinase CK2, increases topo I activity and the cellular sensitivity to topo I-targeted drugs. Topo I hyperphosphorylation also increases its interaction with ARF. Because the ARF-topo I interaction could be highly relevant to DNA metabolism and cancer treatment, we identified the regions of topo I involved in ARF binding and characterized the effects of ARF binding on topo I function. Using a series of topo I deletion constructs, we found that ARF interacted with the topo I core domain, which encompasses most of the catalytic and DNA-interacting residues. ARF binding increased the DNA relaxation activity of hyperphosphorylated topo I by enhancing its association with DNA, but did not affect the topo I catalytic rate. In cells, ARF promoted the chromatin association of hyperphosphorylated, but not basal phosphorylated, topo I, and increased topo I-mediated DNA nicking under conditions of oxidative stress. The aberrant nicking was found to correlate with increased formation of DNA double-strand breaks, which are precursors of many genome destabilizing events. The results suggest that the convergent actions of oxidative stress and elevated CK2 and ARF levels, which are common features of cancer cells, lead to a dysregulation of topo I that may contribute both to the cellular response to topo I-targeted drugs and to genome instability.
authors.affiliation: Torrey Pines Institute for Molecular Studies, San Diego, California, USA.
authors.forename: Keya
authors.initials: K
authors.lastname: Bandyopadhyay
authors.forename: Pingchuan
authors.initials: P
authors.lastname: Li
authors.forename: Ruth A
authors.initials: RA
authors.lastname: Gjerset
mesh_terms: D047390:Casein Kinase II / Q000378:metabolism; D002460:Cell Line; D004264:DNA Topoisomerases, Type I / Q000737:chemistry / Q000378:metabolism*; D004789:Enzyme Activation; D006801:Humans; D016366:Open Reading Frames; D010766:Phosphorylation; D011485:Protein Binding; D054730:Protein Interaction Domains and Motifs; D012694:Serine / Q000378:metabolism; D025803:Tumor Suppressor Protein p14ARF / Q000235:genetics* / Q000378:metabolism*
chemical_list: D025803:Tumor Suppressor Protein p14ARF; D012694:Serine; D047390:Casein Kinase II; D004264:DNA Topoisomerases, Type I
references.citation: Eur J Cancer. 2007 Mar;43(5):928-34
references.pmid: 17267203
references.citation: Clin Cancer Res. 2004 Sep 1;10(17):5792-803
references.pmid: 15355908
references.citation: PLoS One. 2011 Feb 17;6(2):e17193
references.pmid: 21359197
references.citation: Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3496-501
references.pmid: 10097064
references.citation: Science. 1998 Mar 6;279(5356):1534-41
references.pmid: 9488652
references.citation: Science. 1998 Mar 6;279(5356):1504-13
references.pmid: 9488644
references.citation: Science. 2008 Mar 7;319(5868):1352-5
references.pmid: 18323444
references.citation: Lab Invest. 2001 Feb;81(2):217-29
references.pmid: 11232644
references.citation: Biochim Biophys Acta. 1998 Oct 1;1400(1-3):83-105
references.pmid: 9748515
references.citation: Biochemistry. 2007 Dec 11;46(49):14325-34
references.pmid: 18004878
references.citation: J Cell Biol. 1999 Sep 6;146(5):905-16
references.pmid: 10477747
references.citation: Genes Dev. 1998 Aug 1;12(15):2424-33
references.pmid: 9694806
references.citation: Mol Cell Biol. 1996 Apr;16(4):1805-12
references.pmid: 8657156
references.citation: Mucosal Immunol. 2011 Mar;4(2):158-71
references.pmid: 20962773
references.citation: Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13194-9
references.pmid: 9789064
references.citation: FEBS Lett. 1989 Dec 18;259(1):57-60
references.pmid: 2557245
references.citation: Biochemistry. 2011 Feb 8;50(5):704-14
references.pmid: 21182307
references.citation: Mol Cell. 2003 Feb;11(2):415-24
references.pmid: 12620229
references.citation: Oncogene. 2001 Feb 15;20(7):836-48
references.pmid: 11314011
references.citation: Biochem J. 2002 Sep 1;366(Pt 2):653-61
references.pmid: 12027807
references.citation: Genes Dev. 1998 Aug 1;12(15):2434-42
references.pmid: 9694807
references.citation: Oncogene. 2001 May 31;20(25):3247-57
references.pmid: 11423974
references.citation: EMBO J. 1999 Jan 4;18(1):22-7
references.pmid: 9878046
references.citation: J Biol Chem. 1999 Mar 26;274(13):8516-23
references.pmid: 10085084
references.citation: Breast Cancer Res. 2004;6(5):R571-85
references.pmid: 15318938
references.citation: Mol Cell Biol. 2005 Feb;25(4):1258-71
references.pmid: 15684379
references.citation: Mol Med. 1995 Sep;1(6):659-66
references.pmid: 8529132
references.citation: J Biol Chem. 2008 Jun 13;283(24):16711-22
references.pmid: 18408216
references.citation: Mol Biol Rep. 1990 Feb;14(1):35-9
references.pmid: 2161075
references.citation: Mutat Res. 1994 Aug 1;309(1):109-42
references.pmid: 7519727
references.citation: Oncogene. 2000 May 4;19(19):2312-23
references.pmid: 10822382
references.citation: J Biol Chem. 1990 Jun 5;265(16):9418-22
references.pmid: 2160979
references.citation: Cancer Res. 1994 Apr 15;54(8):2262-8
references.pmid: 7513612
references.citation: DNA Repair (Amst). 2006 Sep 8;5(9-10):1126-35
references.pmid: 16807141
references.citation: Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15930-5
references.pmid: 14665695
references.citation: Nat Rev Cancer. 2006 Sep;6(9):663-73
references.pmid: 16915296
references.citation: Pathol Oncol Res. 1999;5(3):171-8
references.pmid: 10491013
references.citation: Proc Natl Acad Sci U S A. 1989 May;86(10):3489-93
references.pmid: 2542933
references.citation: Pathol Int. 2000 Sep;50(9):709-16
references.pmid: 11012984
references.citation: Nucleic Acids Res. 2001 Aug 1;29(15):3195-203
references.pmid: 11470877
references.citation: Int J Biochem Cell Biol. 1999 Sep;31(9):941-9
references.pmid: 10533285
references.citation: Mol Cell. 2002 May;9(5):1031-44
references.pmid: 12049739
references.citation: Annu Rev Biochem. 2001;70:369-413
references.pmid: 11395412
references.citation: Neurosci Behav Physiol. 2003 Oct;33(8):799-804
references.pmid: 14635996
references.citation: Biochemistry. 1988 May 3;27(9):3216-22
references.pmid: 2839226
references.citation: Oncogene. 2006 Dec 7;25(58):7577-86
references.pmid: 16924243
references.citation: DNA Repair (Amst). 2010 Jun 4;9(6):678-89
references.pmid: 20413351
references.citation: Nature. 1998 Sep 10;395(6698):125-6
references.pmid: 9744268
references.citation: Oncogene. 2003 Apr 3;22(13):1945-54
references.pmid: 12673200
references.citation: J Biol Chem. 1983 Dec 25;258(24):15365-70
references.pmid: 6317692
references.citation: Annu Rev Biochem. 1996;65:635-92
references.pmid: 8811192
references.citation: Adv Cancer Res. 2001;80:189-216
references.pmid: 11034544
references.citation: Biochem Biophys Res Commun. 1994 Jul 15;202(1):141-7
references.pmid: 8037705
references.citation: Pathol Res Pract. 2006;202(6):415-24
references.pmid: 16675157
references.citation: Blood. 2002 Feb 15;99(4):1411-8
references.pmid: 11830494
references.citation: PLoS One. 2012;7(11):e50427
references.pmid: 23185622
references.citation: Biochemistry. 2000 Jun 13;39(23):6832-40
references.pmid: 10841763
references.citation: Cancer Res. 1993 Dec 15;53(24):5908-14
references.pmid: 8261402
references.citation: Prostate. 1994;24(1):11-6
references.pmid: 7507238
references.citation: Biochim Biophys Acta. 1981 Aug 27;655(1):1-8
references.pmid: 6266479
references.citation: Nature. 1998 Sep 10;395(6698):124-5
references.pmid: 9744267
references.citation: Cancer Res. 2007 Jun 15;67(12):5667-72
references.pmid: 17575133
references.citation: Biochem Cell Biol. 2004 Dec;82(6):681-93
references.pmid: 15674436
references.citation: Cancer Lett. 1996 Mar 19;101(1):31-5
references.pmid: 8625279